Sarepta Therapeutics Shares Dive After New Gene Therapy Data

Sarepta Therapeutics unveiled new data for its gene therapy to treat Ducchenne muscular dystrophy on Monday. The company said that patients treated with Elevidys showed increased motor function, compared to patients who received placebos at 52 weeks. The Food and Drug Administration has already approved the drug for use in a small patient population, and Sarepta plans to seek an expansion of that approval.